Study on Mosunetuzumab and Lenalidomide Compared to Rituximab and Lenalidomide for Follicular Lymphoma

Inclusion Criteria

• Must have a performance status score of 0, 1, or 2, indicating full activity or some restriction in strenuous activities.
• Must have a confirmed diagnosis of CD20+ follicular lymphoma (Grades 1-3a).
• Must need systemic therapy based on tumor size or specific criteria.
• Must have received at least one prior treatment for lymphoma, including immunotherapy or chemoimmunotherapy.
• Must provide a tumor sample for confirmation of follicular lymphoma diagnosis.
• Must have adequate blood cell counts and organ function.
• Must agree to follow the lenalidomide risk minimization plan, including pregnancy prevention measures.
• Women of childbearing potential must agree to use effective contraception or remain abstinent during and after treatment.
• Men must agree to use contraception or remain abstinent and refrain from donating sperm during and after treatment.

Exclusion Criteria

• Have Grade 3b follicular lymphoma.
• Have a history of transformation to diffuse-large B cell lymphoma.
• Have not responded to lenalidomide or relapsed within 6 months of therapy.
• Have active or past central nervous system lymphoma.
• Have received certain cancer treatments within specified timeframes before the study.
• Have unresolved significant side effects from previous treatments.
• Are taking systemic immunosuppressive medications recently.
• Have a history of organ transplantation.
• Have severe allergic reactions to certain antibodies or components of the study drugs.
• Have a history of severe skin reactions to immunomodulatory drugs.
• Have lung diseases or autoimmune pneumonitis.
• Have active infections or recent major infections.
• Have a history of certain viral infections or liver disease.
• Have active hepatitis B or C, or HIV.
• Have a history of progressive multifocal leukoencephalopathy.
• Have received a live vaccine recently or plan to during the study.
• Have another cancer that could interfere with the study.
• Have active autoimmune diseases requiring treatment.
• Have had a stem cell transplant from a donor.
• Have conditions that prevent safe participation or compliance with the study.
• Have had major surgery recently or plan to during the study.
• Are pregnant, breastfeeding, or planning to become pregnant during the study.
• Have any serious medical conditions that could affect participation or results.